stroke
Conditions
Interventions
Experimental Group:Active tACS
Target Area: Lower limb representation area of the affected primary motor cortex (M1) (1 cm posterior to Cz, 2 cm lateral to the affected side, 10-20 system).
Parameters
Control Group:The electrode placement, interface, and operating procedures are identical to those used for the experimental group. The stimulator delivers a ramp current (0?2 mA?0 mA) only during the
Sponsors
The Third Affiliated Hospital of Sun Yat-sen University
Eligibility
Sex/Gender
All
Age
20 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. First-ever ischemic or hemorrhagic stroke resulting in persistent motor deficits in the affected lower limb; 2. Aged 20 to 75 years; 3. Disease duration of 1 to 12 months; 4. Lesions located in the cerebral cortex or subcortical areas; 5. Patients with stable vital signs and no progression of neurological symptoms. Stable vital signs include normal blood pressure, heart rate, and respiratory rate, and the absence of new-onset neurological deficits such as hemiplegia, aphasia, or altered consciousness, as confirmed by clinical assessment and medical records; 6. Able to walk independently for at least 10 meters (with or without the use of assistive devices such as orthoses or canes); 7. Good cognitive status, with a Mini-Mental State Examination (MMSE) score >= 23.
Exclusion criteria
Exclusion criteria: 1. A history of brain tumor, traumatic brain injury, hydrocephalus, epilepsy, neurodegenerative diseases (e.g., Parkinson's disease, Alzheimer's disease, etc.), autoimmune diseases of the central nervous system, or other severe diseases that may affect the study (including cardiopulmonary, hepatic, renal diseases, etc.); 2. Imaging examination reveals large structural damage in the affected M1 (e.g., complete infarction) or persistently abnormal signals in the lesion area (e.g., unabsorbed hematoma, edema, or gliosis); 3. Presence of metal or electronic implants within the cranium, skull, or orbit (e.g., deep brain stimulation electrodes, cranial repair plates, subdural/epidural electrode grids, aneurysm clips, ventriculoperitoneal shunts, etc.) or implanted electronic devices elsewhere in the body (e.g., cardiac pacemaker, cochlear implant); 4. Severe somatosensory impairment / apraxia / cognitive impairment; 5. Post-craniotomy / skull defect; 6. Lesions located in the cerebellum or brainstem; 7. Presence of pain symptoms affecting walking; 8. More than 2 falls within the past month.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 10-Meter Walking Test; | — |
Secondary
| Measure | Time frame |
|---|---|
| Fugl-Meyer Assessment-lower extremity;Timed Up and Go Test;Berg Balance Scale;Montreal Cognitive Assessment;Gait Analysis;EEG functional connectivity;EEG frequency analysis;Central Motor Conduction Time;Motor Evoked Potential; | — |
Countries
China
Contacts
Public ContactXiquan Hu
The Third Affiliated Hospital of Sun Yat-sen University
Outcome results
None listed